CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

嵌合抗原受体（CAR）T 细胞治疗结局的性别差异

英文原题：Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy.

查看英文原题

Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy.

PubMed 2025/03/01（内容时间） Cancer Med Q2 · IF 3.5（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：CAR-T血液系统恶性肿瘤地区：美国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

在 CAR-T 细胞治疗后，包括早期死亡、30 天再入院和非居家出院在内的住院结局未发现性别差异。

中文摘要

背景

嵌合抗原受体（CAR）T 细胞疗法已成为治疗血液系统恶性肿瘤的革命性方法。本研究旨在评估性别差异对 CAR-T 治疗结局和并发症的影响。

方法

利用 2018–2020 年全美再入院数据库识别患者并分为男性和女性。在根据合并症进行倾向评分匹配后，比较两组住院结局及并发症，形成具有可比性的队列。

结果

共分析 2,928 例患者：男性 1,832 例（62.6%，平均年龄 60.3 ± 13.7 岁），女性 1,096 例（37.4%，平均年龄 59.1 ± 13.8 岁）。按 1:1 倾向评分匹配后，比较 1,092 名男性和 1,092 名女性。两性在早期死亡［校正比值比（aOR）1.04，95% CI 0.69–1.57］、30 天再入院（aOR 1.05，95% CI 0.86–1.30）或出院后未返回家中（aOR 0.89，95% CI 0.60–1.31）方面均无显著差异。女性白细胞减少的比值较高（aOR 1.26，95% CI 1.06–1.50），但急性肾损伤的比值较低（aOR 0.68，95% CI 0.52–0.88）。

结论

CAR-T 治疗后住院结局未发现性别差异，包括早期死亡、30 天再入院和出院后未返回家中。

展开英文摘要原文
BACKGROUND

Chimeric Antigen Receptor (CAR) T-cell therapy has arisen as a revolutionary treatment for hematologic malignancies. Our study aimed to evaluate how sex differences affect outcomes and complications following CAR T-cell therapy.

METHODS

Utilizing the Nationwide Readmissions Database (2018-2020), we identified patients and divided them into male and female groups. Hospital outcomes and complications were compared among these two groups after propensity score matching to match groups based on comorbidities, producing two comparable cohorts.

RESULTS

We analyzed 2928 patients (1832 males, 62.6%, mean age 60.3 13.7 years; 1096 females, 37.4%, mean age 59.1 13.8 years). After propensity score matching (1:1ratio), 1092 males and females were compared. There were no significant sex differences in early mortality (adjusted odd ratios (aOR): 1.04 [95% CI 0.69-1.57]), 30-day readmissions (aOR: 1.05 [95% CI 0.86-1.30]), or nonhome discharge (aOR: 0.89 [95% CI 0.60-1.31]). Females had higher odds of leukopenia (aOR: 1.26 [95% CI 1.06-1.50]) but lower odds of acute kidney injury (aOR: 0.68 [95% CI 0.52-0.88]).

CONCLUSIONS

No sex differences were found in hospital outcomes, including early mortality, 30-day readmission, and nonhome discharge after CAR T-cell therapy.

论文信息

作者
Tan JY、Yeo YH、Kin HWK、Ang QX、Chisti MM、Ezekwudo D、Hilal T
第一作者单位
Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.United States
通讯作者单位
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA.United States
期刊
Cancer medicine2025 Mar
原文标识
PubMed 40129265　·　DOI 10.1002/cam4.70831

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →